Omeros | OMER - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Adma Biologics USD 20.19M 2.86M 2025-12
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Cytokinetics USD 104.9M 13.17M 2026-03
Gilead Sciences USD 1.78B 425M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Immunic USD 3.45M 451K 2025-12
Insmed USD 212.48M 26.11M 2025-12
Knight Therapeutics CAD 35.45M 4.43M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 83.88M 7.99M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Rockwell Medical USD 4.04M 330K 2024-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xoma USD 11M 2.54M 2024-06